EcoDrugPlus

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSAOCG00000007260
Gene Symbol: HTR2B
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSAOCG00000021261
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSAOCG00000021211
Gene Symbol: HTR3B
3 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSAOCG00000023228
Gene Symbol: HTR4
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSAOCG00000015995
Gene Symbol: HTR5A
3 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSAOCG00000002286
Gene Symbol: HTR6
3 Cross references
115 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSAOCG00000001660
Gene Symbol: HTR7
3 Cross references
197 Possible Orthologues:

60s Ribosomal Protein L19-Like

Ensembl ID : ENSAOCG00000022929
Gene Symbol: LOC111566725
4 Cross references
331 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSAOCG00000018934
Gene Symbol: LOC111574442
3 Cross references
383 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSAOCG00000015670
Gene Symbol: LOC111588040
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L3

Ensembl ID : ENSAOCG00000022587
Gene Symbol: LOC111583994
3 Cross references
338 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSAOCG00000008544
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).